BioSpace News Archive

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration has approved the supplemental new drug application for Vemlidy® 25 mg tablets as a once-daily treatment for chronic hepatitis B virus infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today reported financial results for the fourth quarter and full year 2023, recent business highlights, and key upcoming milestones for 2024.

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced the publication of results from the ALIGN-AR Pivotal Trial in The Lancet.

GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”) today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at the MedInvest Biotech & Pharma Investor Conference being held in New York City, NY on Wednesday, April 3, 2024 at 10:10 AM ET.

Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, today announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor.

Canadian-based Noze, a global leader in the breath-based diagnostic space, announced it received a new grant from the Bill & Melinda Gates Foundation, bringing the foundation’s total grant funding to Noze to $1.8 million.

BioSkryb Genomics, a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.

Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM) today announced fourth quarter and year-end financial results for 2023 and provided a corporate update on its development programs.

Octave® Bioscience, Inc. announced the appointment of two key executives, Jeron Evans as Chief Revenue Officer and Debbie Ledet as Chief Access Officer.

Tonix Pharmaceuticals Holding Corp. announced it has entered into a securities purchase agreement with existing healthcare focused institutional investors of the Company for the purchase and sale of 14,666,666 shares of its common stock and warrants to purchase up to an aggregate of 14,666,666 shares of common stock in a registered direct offering at a combined offering price of $0.30 per share and accompanying warrant.